Partnership insights

Collaborating, innovating, and finding new ways together to improve outcomes

Much more can be achieved when all players in the life sciences and pharmaceutical industries work together, in a truly collaborative way. At ICON, this means working in a way that goes beyond a traditional CRO. It means being a trusted partner.

Exploring partnership culture and its impact on outsourcing and operational strategy

Partnership culture within the clinical research industry has often been overlooked as a component of a successful outsourcing strategy. However, culture can support, inform, and maintain strategies and operational decision-making.

Read the whitepaper

Webinar: Exploring partnership culture and its impact on outsourcing and operational strategy

In this webinar, Sanofi and ICON discuss how they created a shared partnership/alliance culture, which has evolved both the outsourcing strategy and operating model. Attendees will learn about the specific tools and methods used to develop and support the Sanofi / ICON partnership, including:

  • Adaptation of the 9 Box Grid to assess cultural alignment and outsourcing and operational strategy, identifying areas of strength and opportunities for development
  • An “ABCs of Culture” framework, designed to build cross-organisational cultural alignment.
Watch the webinar

The evolving relationship between sponsors and CROs

In this Q&A and accompanying podcast, Jeff James provides his perspectives on how CROs have matured to become true partners that offer expansive clinical trial and drug development services, and he spotlights ICON’s approach towards collaboration.

Read the article

Sponsor and CRO pharmacovigilance and safety alliances

This whitepaper outlines the best practices and model options for ensuring success when outsourcing pharmacovigilance and patient safety services.

Read the whitepaper

Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups

With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.

Watch the webinar

Engaging physicians to support and increase clinical research activity

More and more healthcare institutions are looking to increase their research portfolio however engagement of busy physicians is always a challenge.

Watch the webinar